Sun Pharmaceutical Industries has reported results for the quarter and year ended March 31, 2012.
The company’s net profit for the fourth quarter ended March 31, 2012 rose 88.31% to Rs 702.00 crore as compared to Rs 372.78 crore for the quarter ended March 31, 2011. The total income has increased by 60.04% to Rs 1388.68 crore for the quarter under review from Rs 867.72 crore for the corresponding quarter of the previous year.
For the year ended March 31, 2012, the company’s net profit jumped by 39.33% to Rs 1927.98 crore as compared to Rs 1383.80 crore for the previous year. The company’s total income has increased by 30.33% to Rs 4303.91 crore for the year from Rs 3302.30 crore in the previous year.
On consolidated basis, the Group’s net profit after tax and minority interest stood at Rs 2587.25 crore for the year under review as compared to Rs 1816.06 crore for the period ago, up by 42.47%. Its total income has increased by 38.51% to Rs 8429.69 crore for the year ended March 31, 2012 from Rs 6085.75 crore in the previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: